Choose a date range

From To

Choose one or more categories


Show only original CenterWatch stories


Pharmatech launches recruiting solution, Just-In-Time model

Friday, June 19, 2015 10:47 AM

Pharmatech, a Denver-based oncology CRO, is changing how clinical trials studies enroll cancer patients by offering a patient-centered, on-demand research alternative. Pharmatech helps cancer patients identify the right trial opportunity, then activates that trial at a nearby treatment center using a Just-In-Time delivery model.

More... »

Quest Diagnostics

ICON launches Firecrest Patient Portal to enhance informed consent education

Friday, June 19, 2015 10:38 AM

Global CRO Icon has launched the Firecrest Patient Portal. This portal enables patients to view clinical trial information and is specifically designed to enhance the patients’ understanding of treatment before consenting to participate at an investigator site.

More... »

Heron Therapeutics initiates phase II trial of HTX-011 for post-operative pain

Wednesday, June 17, 2015 10:53 AM

Heron Therapeutics has initiated a phase II clinical trial of HTX-011, the company’s lead product candidate for the prevention of post-operative pain, following clearance from the FDA of its IND application for HTX-011. HTX-011, which utilizes Heron’s proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam.

More... »

Protalex receives FDA Orphan designation for PRTX-100 to treat immune thrombocytopenia

Wednesday, June 17, 2015 10:46 AM

The FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug designation to Protalex’s PRTX-100 for the treatment of immune thrombocytopenia (ITP). PRTX-100, Protalex’s lead product, is a highly purified form of Staphylococcal Protein A. The FDA previously accepted the company’s IND application for a phase I/II open-label, dose-escalating study of PRTX-100 in adults with persistent/chronic ITP. Protalex expects to enroll its first patient in an ITP study in the third quarter of 2015.

More... »

Ocular Therapeutix begins enrollment in phase III trial for allergic conjunctivitis

Wednesday, June 17, 2015 10:41 AM

Ocular Therapeutix, a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, has enrolled its first patients in a phase III clinical trial to evaluate the safety and efficacy of Dextenza (sustained release dexamethasone, 0.4mg) for the treatment of allergic conjunctivitis. Dextenza is administered by a physician as a bioresorbable intracanalicular depot for drug release to the ocular surface for up 30 days.

More... »

Report: Pharma R&D pipeline value jumps 18% to $493 billion

Wednesday, June 17, 2015 10:32 AM

Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the U.S. and Europe, fueling a projected 5% increase in global prescription sales over the next five years, according to the EvaluatePharma World Preview 2015, Outlook to 2020 report from life science market intelligence firm Evaluate. With the FDA approving an unprecedented 50 drugs in 2014, eight of which are forecast to have sales of more than $1 billion five years after launch, sustained R&D productivity may finally be within reach.

More... »

Abbott will vote its Mylan shares in favor of Mylan's proposed acquisition of Perrigo

Wednesday, June 17, 2015 09:51 AM

Abbott has confirmed its continued support for Mylan's growth strategy by stating its intent to vote its 14.5% stake in Mylan in favor of Mylan's proposed acquisition of Perrigo.

More... »

Medivir restructures, partners with GVK BIO

Wednesday, June 17, 2015 09:48 AM

Medivir, a research based pharmaceutical company based in Sweden, has announced a reorganization within its Discovery Research department, increasing its focus within the core areas of oncology and infectious diseases, and a partnership with GVK Biosciences Private (GVK BIO) of Hyderabad in India, designed to deliver enhanced efficiency and quality within its portfolio of research projects while over time reducing overall research costs and enhancing future cost flexibility.

More... »

MLSC, COBTH, UMass Med launch web portal to promote collaboration

Wednesday, June 17, 2015 09:38 AM

The Massachusetts Life Sciences Center (MLSC) partnered with the Conference of Boston Teaching Hospitals (COBTH) and the University of Massachusetts Memorial Medical Center to the launch the Massachusetts Clinical Innovation Gateway. The new web portal will allow life sciences companies from around the world to seek opportunities to partner with Massachusetts academic medical centers (AMCs) on research and clinical initiatives.

More... »

GSK launches Altius Institute for Biomedical Sciences

Wednesday, June 17, 2015 09:25 AM

GlaxoSmithKline is launching the Altius Institute for Biomedical Sciences, an independent, nonprofit research institute in Seattle. Altius will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions in health and disease. GSK expects to capitalize on rapid progress in understanding gene control to select and validate better drug targets, and to accelerate many key aspects of developing new medicines.

More... »


June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs